Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
PFIZER ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PFIZER Mar-23 |
ADCOCK INGRAM Jun-14 |
PFIZER/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 4,662 | 319 | - | |
Low | Rs | 3,407 | 230 | - | |
Sales per share (Unadj.) | Rs | 530.0 | 94.9 | - | |
Earnings per share (Unadj.) | Rs | 136.4 | -23.9 | - | |
Cash flow per share (Unadj.) | Rs | 159.4 | -19.8 | - | |
Dividends per share (Unadj.) | Rs | 70.00 | 0 | - | |
Avg Dividend yield | % | 1.7 | 0 | - | |
Book value per share (Unadj.) | Rs | 701.0 | 74.5 | - | |
Shares outstanding (eoy) | m | 45.75 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 7.6 | 2.9 | 263.1% | |
Avg P/E ratio | x | 29.6 | -11.5 | -257.6% | |
P/CF ratio (eoy) | x | 25.3 | -13.9 | -182.6% | |
Price / Book Value ratio | x | 5.8 | 3.7 | 156.1% | |
Dividend payout | % | 51.3 | 0 | - | |
Avg Mkt Cap | Rs m | 184,576 | 46,340 | 398.3% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 3,317 | 2,908 | 114.0% | |
Avg. sales/employee | Rs Th | 0 | 3,730.7 | - | |
Avg. wages/employee | Rs Th | 0 | 677.5 | - | |
Avg. net profit/employee | Rs Th | 0 | -940.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 24,248 | 16,016 | 151.4% | |
Other income | Rs m | 1,011 | 112 | 901.0% | |
Total revenues | Rs m | 25,258 | 16,128 | 156.6% | |
Gross profit | Rs m | 8,420 | -2,775 | -303.4% | |
Depreciation | Rs m | 1,055 | 691 | 152.6% | |
Interest | Rs m | 135 | 434 | 31.1% | |
Profit before tax | Rs m | 8,240 | -3,788 | -217.5% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,001 | 237 | 845.2% | |
Profit after tax | Rs m | 6,239 | -4,036 | -154.6% | |
Gross profit margin | % | 34.7 | -17.3 | -200.4% | |
Effective tax rate | % | 24.3 | -6.2 | -388.6% | |
Net profit margin | % | 25.7 | -25.2 | -102.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 24,933 | 11,730 | 212.6% | |
Current liabilities | Rs m | 6,574 | 6,600 | 99.6% | |
Net working cap to sales | % | 75.7 | 32.0 | 236.4% | |
Current ratio | x | 3.8 | 1.8 | 213.4% | |
Inventory Days | Days | 93 | 111 | 84.3% | |
Debtors Days | Days | 2 | 124 | 1.8% | |
Net fixed assets | Rs m | 13,780 | 6,838 | 201.5% | |
Share capital | Rs m | 458 | 74 | 615.3% | |
Net worth | Rs m | 32,073 | 12,571 | 255.1% | |
Long term debt | Rs m | 0 | 4,418 | 0.0% | |
Total assets | Rs m | 39,031 | 23,747 | 164.4% | |
Interest coverage | x | 62.1 | -7.7 | -803.5% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.7 | 92.1% | |
Return on assets | % | 16.3 | -15.2 | -107.7% | |
Return on equity | % | 19.5 | -32.1 | -60.6% | |
Return on capital | % | 26.1 | -19.8 | -131.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,557 | 1,367 | 260.2% | |
From Investments | Rs m | -361 | -420 | 85.9% | |
From Financial Activity | Rs m | -3,458 | 4,009 | -86.2% | |
Net Cashflow | Rs m | -262 | 4,957 | -5.3% |
Compare PFIZER With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare PFIZER With: ERIS LIFESCIENCES BACIL PHARMA VINEET LABORATORIES CIPLA ISHITA DRUGS
Indian share markets Slipped further as the session progressed and ended the day weak.